Physician profile
Michael T Hemphill
NPI 1255691960
$12,776.38
in general payments reported to CMS, 2019-2025
32 companies · $447 in 2025
The $447 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,146 · 2021: $13.54 · 2022: $2,379 · 2023: $8,209 · 2024: $582 · 2025: $447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $6,900 · Travel and Lodging: $1,092 · Food and Beverage: $1,005 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $6,900.00 |
| Travel and Lodging | $1,091.69 |
| Food and Beverage | $1,005.08 |
| Education | $240.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $8,079.76 | 2019-2023 | Ocrevus, Enspryng |
| Genentech, INC. | $2,295.00 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $481.62 | 2019-2025 | Fasenra, Airsupra, Tezspire |
| Glaxosmithkline, LLC. | $277.62 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Allergan, INC. | $242.13 | 2019 | |
| Gilead Sciences, INC. | $177.50 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $155.73 | 2019-2025 | Ofev, Jascayd |
| Inogen, INC. | $143.32 | 2023-2025 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Actelion Pharmaceuticals US, INC. | $138.68 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $115.10 | 2024 | Dupixent |
| Sanofi-Aventis U.S. LLC | $99.95 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $68.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $54.94 | 2019-2025 | |
| Verona Pharma, INC. | $46.72 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $40.18 | 2019 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $35.80 | 2019 | |
| Vifor Pharma, INC. | $34.47 | 2019 | |
| Portola Pharmaceuticals, LLC | $33.91 | 2019 | |
| Genzyme Corporation | $30.44 | 2024 | |
| United Therapeutics Corporation | $25.46 | 2023 | Tyvaso |
| Sunovion Pharmaceuticals INC. | $24.45 | 2019 | |
| Baxter Healthcare | $22.69 | 2025 | Hillrom - Carnation Ambulatory Monitor |
| Chiesi USA, INC. | $19.35 | 2019 | |
| Edwards Lifesciences Corporation | $18.22 | 2019 | |
| Viatris Specialty LLC | $17.93 | 2025 | Yupelri |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $15.68 | 2025 | Lifevest |
| Exelixis INC. | $15.19 | 2022 | |
| Amgen INC. | $14.73 | 2025 | Tezspire |
| Mylan Specialty L.P. | $14.42 | 2024 | Yupelri |
| Mallinckrodt Enterprises LLC | $13.24 | 2019 | |
| Electromed, INC. | $12.61 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $11.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Hemphill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.